Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

Abstract Background In 2019, the World Health Organisation (WHO) recommended Dolutegravir (DTG) as the preferred first-line antiretroviral treatment (ART) for all persons with HIV. ART regimen switches may affect HIV treatment adherence. We sought to describe patient experiences switching from EFV t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Adelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, Florence Ajok, Henry Onen, Ivan Kalule, Phoebe Kajubi, Kay Seden, Noela Owarwo, Agnes Kiragga, Mari Armstrong-Hough, Anne Katahoire, Andrew Mujugira, Mohammed Lamorde, Barbara Castelnuovo
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
HIV
Dolutegravir
Drug switching
Qualitative research
Uganda
Infectious and parasitic diseases
RC109-216
Acceso en línea:https://doaj.org/article/4e44c82667bb4af7ad5d72f67e6e462a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/4e44c82667bb4af7ad5d72f67e6e462a

Ejemplares similares